Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Equity Average (2020 - 2025)

Silence Therapeutics' Equity Average history spans 6 years, with the latest figure at $68.2 million for Q4 2025.

  • For Q4 2025, Equity Average fell 47.7% year-over-year to $68.2 million; the TTM value through Dec 2025 reached $68.2 million, down 47.7%, while the annual FY2025 figure was $98.2 million, 25.84% up from the prior year.
  • Equity Average for Q4 2025 was $68.2 million at Silence Therapeutics, down from $84.1 million in the prior quarter.
  • Across five years, Equity Average topped out at $149.6 million in Q2 2024 and bottomed at $11.7 million in Q4 2021.
  • The 5-year median for Equity Average is $89.0 million (2024), against an average of $85.1 million.
  • The largest annual shift saw Equity Average skyrocketed 454.13% in 2024 before it tumbled 47.7% in 2025.
  • A 5-year view of Equity Average shows it stood at $11.7 million in 2021, then skyrocketed by 59.38% to $18.7 million in 2022, then rose by 25.86% to $23.5 million in 2023, then surged by 454.13% to $130.4 million in 2024, then tumbled by 47.7% to $68.2 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Equity Average are $68.2 million (Q4 2025), $84.1 million (Q3 2025), and $103.4 million (Q2 2025).